Neoprobe Corp. has faced a rough road over the past couple of months, first with the loss in October of its worldwide marketing partner, U.S. Surgical Corp., and last week with the presumably temporary withdrawal of its European marketing application for RIGScan. As a result, it's now unclear when the product will receive European marketing approval, and how well NEOP will do in marketing the product on its own.

NEOP withdrew the European application for its radiolabeled monoclonal antibody for the surgical detection of metastatic colorectal cancer following